SLCO1B1 encodes the organic anion transporting polypeptide 1B1 (OATP1B1), a liver uptake transporter that moves statins from the blood into liver cells where they exert their cholesterol-lowering effect. When this transporter does not work properly, statins accumulate in the blood and muscle tissue instead of entering the liver, dramatically increasing the risk of myopathy¹¹ Myopathy: disease of muscle tissue, ranging from mild pain to serious breakdown.

The Mechanism

The SLCO1B1*5 variant²² rs4149056 causes a valine-to-alanine substitution at position 174³³ Amino acid change: valine to alanine at position 174 (V174A) in a transmembrane domain of the transporter. This reduces the transporter's ability to move statins into liver cells. The C allele produces a transporter with markedly reduced function, leading to higher systemic statin exposure -- approximately 40% higher simvastatin acid levels⁴⁴ 40% higher simvastatin acid levels
CPIC guideline for SLCO1B1 in heterozygous carriers.

The SEARCH Trial

The landmark SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial⁵⁵ SEARCH (Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine) trial
SEARCH Collaborative Group. NEJM, 2008 identified SLCO1B1*5 as the primary genetic determinant of statin-induced myopathy. Homozygous carriers (CC) had a 17-fold increased risk of myopathy on simvastatin 80mg (OR 16.9, 95% CI 4.7-61.1), while heterozygous carriers (CT) had a 4.5-fold increased risk (OR 4.5, 95% CI 2.6-7.7). This finding led to the FDA limiting the maximum recommended dose of simvastatin to 40mg.

Not All Statins Are Equal

The risk varies significantly by statin type. Simvastatin is the highest risk because it relies heavily on SLCO1B1 for liver uptake. Pravastatin is the safest alternative because it enters liver cells through multiple pathways and is less dependent on SLCO1B1. Rosuvastatin has intermediate risk. Atorvastatin uses SLCO1B1 but has a wider therapeutic window than simvastatin. The 2022 CPIC guideline update⁶⁶ 2022 CPIC guideline update
Cooper-DeHoff RM et al. CPIC guideline for statins and SLCO1B1, ABCG2, CYP2C9. Clin Pharmacol Ther, 2022 now covers all statins, not just simvastatin.

Practical Implications

If you carry the C allele and ever need statin therapy, this information can prevent a potentially serious adverse reaction. Statin-induced myopathy ranges from mild muscle aches to rhabdomyolysis⁷⁷ Rhabdomyolysis: severe muscle breakdown that releases proteins into the blood, potentially damaging the kidneys. Choosing the right statin and dose based on your SLCO1B1 genotype is one of the clearest wins in clinical pharmacogenomics.

COMT (catechol-O-methyltransferase) ¹¹ COMT methylates and inactivates catechol-containing compounds including dopamine, estrogens, and certain drugs is an enzyme that breaks down catecholamines — dopamine, norepinephrine, and epinephrine — by adding a methyl group from SAM. The Val158Met variant (rs4680) is one of the most fascinating genetic variants because it doesn't have a clear "good" or "bad" allele. Instead, each version confers different cognitive and behavioral trade-offs.

The Mechanism

The A allele (Met) ²² Val158Met: valine-to-methionine substitution at position 158 of the enzyme (p.Val158Met) produces an enzyme that works 3-4 times slower than the G allele (Val) version. Methionine at position 158 makes the enzyme thermolabile, reducing its catalytic efficiency at body temperature. Slower COMT means dopamine and other catecholamines persist longer in the prefrontal cortex, the brain region responsible for working memory, planning, and executive function ³³ The prefrontal cortex is uniquely dependent on COMT for dopamine clearance because it lacks the dopamine transporter found in other brain regions.

Warrior vs. Worrier

The GG (Val/Val) "warrior" genotype breaks down dopamine quickly, resulting in lower prefrontal dopamine levels. Warriors perform better under stress and pressure but may have less optimal baseline cognitive performance. The AA (Met/Met) "worrier" genotype maintains higher dopamine levels, leading to better cognitive performance in calm conditions but greater vulnerability to stress and anxiety. This cognitive trade-off was demonstrated in a landmark study by Egan et al.⁴⁴ landmark study by Egan et al.
Egan MF et al. COMT Val158Met effects on prefrontal cortex function, 2001.

Pain and Opioid Response

COMT genotype significantly affects pain sensitivity and opioid response. The Zubieta landmark study⁵⁵ Zubieta landmark study
Zubieta JK et al. COMT Val158Met affects mu-opioid neurotransmitter responses to pain, 2003 showed that Met/Met individuals have diminished mu-opioid responses to pain. A study on cancer patients⁶⁶ study on cancer patients
Rakvag TT et al. COMT Val158Met influences morphine requirements in cancer pain patients, 2005 found that Val/Val patients needed 63% higher morphine doses than Met/Met patients. A meta-analysis⁷⁷ meta-analysis
Chen YC et al. COMT Val158Met and postoperative opioid consumption, 2018 confirmed reduced opioid consumption in Met carriers.

The Methylation Connection

COMT uses SAM as its methyl donor, directly linking it to the methylation cycle. Slow COMT (AA) individuals are more sensitive to methyl donors like methylfolate, methylB12, and TMG ⁸⁸ Trimethylglycine (betaine): a potent methyl donor derived from choline that feeds into the methylation cycle (trimethylglycine). Excess methyl groups can overstimulate an already slow COMT pathway, causing anxiety, irritability, and insomnia. This is why some people feel worse on high-dose methylated B vitamins.

Practical Implications

If you are AA (slow COMT), be cautious with methyl donor supplements. Start with low doses and increase gradually. Folinic acid and hydroxocobalamin are gentler alternatives to methylfolate and methylcobalamin. Glycine (2-4g) can help buffer excess methyl groups. If you are GG (fast COMT), you generally tolerate methyl donors well and may even benefit from them. This variant is key to personalizing your methylation support strategy.

Interactions

COMT interacts with MTHFR (rs1801133) — MTHFR determines methylfolate production while COMT determines tolerance. Someone with both MTHFR AA (low methylfolate) and COMT AA (slow methylation) faces a complex supplementation challenge.

DYRK1B (Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1B) is a serine/threonine kinase that plays a pivotal role in adipogenesis, glucose homeostasis, and hedgehog/Wnt signaling pathways. When functioning normally, DYRK1B helps restrain fat cell differentiation and maintain metabolic balance. The H90P variant disrupts a critical structural element of the kinase, triggering a cascade of metabolic consequences that manifest as AOMS3¹¹ AOMS3
Abdominal Obesity-Metabolic Syndrome 3, OMIM #615812, a rare autosomal dominant condition causing severe early-onset metabolic syndrome.

The Mechanism

The H90P mutation replaces histidine with proline at position 90 of the protein, within the DYRK homology (DH) box²² DYRK homology (DH) box
A conserved structural element immediately preceding the catalytic domain, critical for proper kinase folding through tyrosine autophosphorylation. This box normally stabilizes interactions with the catalytic domain during protein maturation. The substitution impairs tyrosine autophosphorylation (reduced ~80% versus wild-type), causing mutant DYRK1B to misfold and accumulate in detergent-insoluble cytoplasmic aggregates. The result is a net loss of functional DYRK1B activity.

Without adequate DYRK1B function, two main pathological effects follow: enhanced adipogenesis — preadipocytes differentiate more readily into fat cells, leading to accelerated visceral fat accumulation — and impaired glucose regulation — hepatic glucose-6-phosphatase expression rises, driving excess hepatic glucose output and contributing to frank type 2 diabetes. Downstream, the RAS–RAF–MEK pathway is dysregulated, and suppression of hedgehog and Wnt signaling further promotes adipogenic commitment of precursor cells.

The Evidence

The H90P variant was first described in 2014³³ first described in 2014
Keramati AR et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med. 2014;370(20):1909-19 through genetic linkage analysis and whole-exome sequencing of three large Iranian families with autosomal dominant metabolic syndrome. H90P co-segregated with disease in an ethnically distinct family alongside the R102C mutation, producing an identical phenotype: early-onset central obesity, type 2 diabetes, hypertension, and coronary artery disease (myocardial infarction between ages 50–60). No unaffected carrier was identified in any family, suggesting high penetrance.

Molecular characterization⁴⁴ Molecular characterization
Abu Jhaisha S et al. DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain. Sci Rep. 2017;7(1):7602 confirmed that H90P — unlike the structurally intact mature kinase — fails to properly autophosphorylate on tyrosine. The mutant protein relies abnormally on the HSP90–CDC37 chaperone complex for stability, rendering it sensitive to HSP90 inhibition. This chaperone dependency is a therapeutic vulnerability that has been proposed as a drug target.

A 2024 Diabetes Care study⁵⁵ 2024 Diabetes Care study
Folon L et al. Pathogenic, Total Loss-of-Function DYRK1B Variants Cause Monogenic Obesity Associated With Type 2 Diabetes. Diabetes Care. 2024 across 9,353 participants quantified the effect: pathogenic DYRK1B loss-of-function variants were associated with an 8.0-unit higher BMI (OR 7.9 for obesity) and OR 4.8 for type 2 diabetes. The same study confirmed that H90P-class variants cause monogenic obesity, a clinically distinct entity from polygenic common obesity.

What This Means Clinically

AOMS3 is frequently misdiagnosed. A 2024 case report⁶⁶ 2024 case report
Abdominal Obesity-Metabolic Syndrome 3 Misclassified as Type 1 Diabetes Mellitus. 2024 documented a patient treated with 225 units of insulin daily for 15 years before the DYRK1B mutation was identified. Switching to oral agents (metformin, pioglitazone, dapagliflozin) plus semaglutide reduced HbA1c from 13% to 7% within 6 months — a result insulin alone had never achieved. DYRK1B carriers respond better to insulin-sensitizing agents and GLP-1 receptor agonists than to exogenous insulin.

Because this is an autosomal dominant condition, each first-degree relative of a carrier has a 50% chance of inheriting the variant. Early identification before metabolic complications emerge allows preventive intervention.

H90R — The Second Allele at This Codon

This locus is multi-allelic: in addition to H90P (T>G), a T>C change at the same position produces H90R (His90Arg). H90R has not been individually characterised in cell-based assays, but its structural logic is equivalent — arginine, like proline, disrupts the local backbone geometry of the DH box required for tyrosine autophosphorylation during kinase maturation. Population data (gnomAD v4 exomes, ~3 alleles in 800,000) confirms the same extreme rarity as H90P. H90R is classified as likely pathogenic by structural inference; clinical management for carriers is identical to H90P.

Interactions

H90P and H90R act at the same codon as the R102C variant (encoded by a distinct mutation in the same DYRK1B gene at codon 102). All three disrupt the DH box and produce clinically indistinguishable AOMS3. Functional studies on H90P and R102C show overlapping mechanisms — impaired DH-box-mediated kinase maturation, enhanced chaperone dependency, and downstream adipogenic dysregulation — making them phenotypic equivalents despite different amino acid substitutions.

Your thyroid gland operates like a thermostat: the pituitary hormone TSH (thyroid-stimulating hormone)¹¹ TSH (thyroid-stimulating hormone)
Thyrotropin — secreted by the anterior pituitary, it binds TSH receptors on thyroid follicular cells and drives synthesis and release of T3 and T4. The pituitary adjusts TSH output based on feedback from circulating thyroid hormone levels signals the thyroid to produce more or less hormone. But the gain on that thermostat varies between individuals — and PDE8B is a key control knob.

PDE8B encodes phosphodiesterase 8B²² phosphodiesterase 8B
A cyclic nucleotide phosphodiesterase highly expressed in thyroid tissue that specifically degrades cAMP (cyclic adenosine monophosphate). cAMP is the second messenger through which TSH stimulates thyroid hormone production an enzyme that degrades cAMP inside thyroid follicular cells. When TSH binds its receptor, it triggers a cAMP surge that drives thyroid hormone synthesis. PDE8B acts as a brake on that surge: higher PDE8B activity → faster cAMP degradation → weaker thyroid response to TSH → the pituitary compensates by raising circulating TSH levels. rs6885099 sits in intron 1 of PDE8B and influences how much of this enzyme the thyroid makes.

The Mechanism

rs6885099 is an intronic quantitative trait locus (QTL)³³ quantitative trait locus (QTL)
A genetic variant that influences the quantity of a measurable trait — here, serum TSH levels — without altering protein structure. These variants typically act through regulatory elements (enhancers, splicing signals) embedded within introns or non-coding regions affecting PDE8B gene expression in thyroid tissue. The G allele is associated with higher PDE8B activity or expression, which accelerates cAMP degradation and raises the thyroid's effective TSH threshold. The result is a genetically-programmed upward shift in the individual's TSH set-point — circulating TSH is chronically higher relative to tissue thyroid hormone levels.

Critically, this is not the same as thyroid disease: individuals with GG or AG genotypes have a higher TSH set-point but are often euthyroid (normal circulating T3/T4). However, they may tip into subclinical hypothyroidism⁴⁴ subclinical hypothyroidism
TSH above the upper reference range with normal free T4 — the most common form of thyroid dysfunction, affecting 4-10% of the general population and up to 20% of women over 60 at lower absolute levels of thyroid dysfunction, and when they do require levothyroxine replacement, their genetically higher set-point may require a higher dose to suppress TSH adequately.

The Evidence

The largest study to date is the Rand et al. 2025⁵⁵ Rand et al. 2025
Rand SA et al. Genome-wide association study and polygenic risk prediction of hypothyroidism. Nat Genet, 2025 meta-analysis in 113,393 hypothyroidism cases and 1,065,268 controls — identifying 350 associated loci. rs6885099-G showed one of the strongest signals (beta = 0.10, p = 1×10⁻⁹³), confirming PDE8B as a major determinant of hypothyroidism susceptibility.

The TSH-lowering effect of the A allele was established by Porcu et al. 2013⁶⁶ Porcu et al. 2013
Porcu E et al. A meta-analysis of thyroid-related traits reveals novel loci and gender-specific differences in the regulation of thyroid function. PLoS Genet, 2013 in up to 26,420 euthyroid subjects: the rs6885099-A allele reduced log-TSH by 0.141 units (p = 2×10⁻²⁶), with a stronger effect in males (beta −0.168, p = 3×10⁻³⁸) than females (beta −0.12, p = 6×10⁻²⁴), suggesting partial sex-hormone modulation of PDE8B activity.

Soto-Pedre et al. 2017⁷⁷ Soto-Pedre et al. 2017
Soto-Pedre E et al. Replication confirms the association of loci in FOXE1, PDE8B, CAPZB and PDE10A with thyroid traits: a GoDARTS study. Pharmacogenet Genomics, 2017 confirmed the locus in 1,703 hypothyroidism cases and 9,457 controls; PDE8B variants collectively explained 6.8% of TSH variance.

Wade et al. 2025⁸⁸ Wade et al. 2025
Wade AN et al. Strength of Genetic Associations with Thyrotropin Values Differs Between Populations with Similarity to African and European Reference Populations. Thyroid, 2025 found that PDE8B was not significantly associated with TSH in African-ancestry populations despite strong effects in Europeans — an important caveat for interpreting the result in non-European individuals.

Practical Actions

For GG and AG individuals, the main clinical implications are: (1) awareness of a higher baseline TSH that may require lower thresholds for hypothyroidism diagnosis, (2) for those already on levothyroxine, the TSH target may need adjustment relative to standard ranges, and (3) monitoring iodine intake — since thyroid hormone synthesis requires iodine, marginal iodine status combined with a high-PDE8B set-point amplifies hypothyroidism risk.

Selenium supports deiodinase enzymes⁹⁹ deiodinase enzymes
Selenoproteins that convert the storage form T4 to the active T3; selenium deficiency impairs this conversion and may worsen functional hypothyroidism even when TSH is only mildly elevated that convert inactive T4 to active T3. GG carriers benefit specifically from ensuring selenium adequacy.

Interactions

rs4704397 (PDE8B intron 1) is in strong linkage disequilibrium with rs6885099 and captures overlapping variance. Both variants have been studied for TSH effects; their combined information adds little beyond either alone.

rs2046045 (PDE8B intron 1) is a third correlated variant in the same LD block, consistently identified in GWAS of TSH and hypothyroidism.

rs11206244 (TPO — thyroid peroxidase) affects thyroid hormone synthesis directly rather than cAMP signaling, acting through a different pathway. Individuals combining a high PDE8B set-point (this SNP) with impaired TPO activity may have compounded hypothyroidism risk.

Endothelial lipase (EL), encoded by the LIPG gene on chromosome 18, is the primary enzyme responsible for breaking down the phospholipid surface of HDL particles¹¹ HDL particles
High-density lipoprotein — the "good cholesterol" carrier that transports cholesterol from peripheral tissues back to the liver for clearance. Unlike lipoprotein lipase (which targets triglyceride-rich VLDL and chylomicrons), EL preferentially hydrolyzes HDL phospholipids. Higher EL activity accelerates HDL catabolism, reducing circulating HDL-C. The rs9951026 variant is an intronic tag SNP in LIPG that marks a broader haplotype structure associated with modestly altered LDL cholesterol and apolipoprotein B levels — with an important twist: the effect on lipid profiles is substantially modified by physical activity.

The Mechanism

As a non-coding intronic variant, rs9951026 does not directly change any amino acid in the endothelial lipase protein. Its association with lipid traits derives from linkage disequilibrium²² linkage disequilibrium
LD — the tendency for nearby genetic variants to be inherited together on the same chromosomal segment, so that one variant predicts the presence of another with functional regulatory variants in the same LIPG haplotype block. The TTACA LIPG haplotype — spanning rs2000812, rs2000813, rs8093249, rs2276269, and rs9951026 — has been associated with higher LDL cholesterol and apolipoprotein B concentrations in population studies, suggesting the haplotype affects either LIPG expression levels or broader lipoprotein remodeling through regulatory elements in the same LD block.

LIPG expression is upregulated by pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6³³ pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-6
The inflammatory connection explains why conditions like atherosclerosis, infection, and metabolic syndrome all tend to lower HDL-C — inflammation drives LIPG activity, which then degrades HDL faster. Physical activity suppresses this inflammatory signaling, which may explain why the lipid associations at rs9951026 are primarily visible in sedentary individuals: active individuals have lower baseline LIPG expression through reduced inflammation, partially neutralizing the haplotype effect.

The Evidence

Salazar-Tortosa et al. (2022)⁴⁴ Salazar-Tortosa et al. (2022)
Interplay of physical activity and genetic variants of the endothelial lipase on cardiovascular disease risk factors; 1,057 European adolescents from the HELENA Study aged 12–18 years; Pediatric Research found that the minor G allele of rs9951026 was associated with lower CVD risk factors related to the lipid profile. Critically, the beneficial allele associations were observed specifically in physically active adolescents — not in sedentary participants. The gene-physical activity interaction was statistically significant for rs9951026 (along with rs2000813 and rs2276269), indicating that the genetic effect on cardiovascular risk factors depends substantially on activity level.

The broader LIPG haplotype context comes from Hutter et al. (2006)⁵⁵ Hutter et al. (2006)
Association of endothelial lipase gene haplotypes with HDL cholesterol subfractions and apolipoprotein AI plasma levels in Japanese Americans; 541 adult participants; Atherosclerosis, which found that LIPG haplotypes — including variants at the same chromosomal region as rs9951026 — influenced HDL3 cholesterol (p=0.005) and apolipoprotein A-I levels (p=0.002), with favorable haplotype combinations showing lower apolipoprotein B and LDL cholesterol (p=0.001 and p=0.015 respectively).

Edmondson et al. (2009)⁶⁶ Edmondson et al. (2009)
Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans; 585 participants with extreme HDL phenotypes plus meta-analysis of ~3,845 participants; J Clin Invest established the fundamental LIPG-HDL relationship: rare loss-of-function mutations in LIPG raise HDL by approximately 8–11 mg/dL (10–16%), validating EL as a key determinant of circulating HDL levels in humans. While rs9951026 is not a loss-of-function variant, it sits in a haplotype context that modulates EL's functional output.

Practical Actions

The most important insight from the evidence is the gene-activity interaction: the A allele haplotype's association with less favorable lipid levels is attenuated or reversed in physically active individuals. This is not a reason to reduce cardiorespiratory training — it is a signal that your genetic lipid risk from this variant is disproportionately responsive to activity levels compared to the population average. Cardiovascular exercise reduces systemic inflammation, which in turn suppresses LIPG expression and slows HDL catabolism, partially compensating for an unfavorable LIPG haplotype.

For AA homozygotes, the standard lipid panel remains the key monitoring tool. Saturated fat quality, omega-3 intake, and aerobic activity are the primary levers — and for this genotype, activity matters more than average. Regular fasting lipid panels (including LDL-C and apolipoprotein B if available) provide the most actionable feedback.

Interactions

rs9951026 is part of a multi-SNP LIPG haplotype that includes rs2000813 (the Thr111Ile coding variant), rs3813082, and rs2276269. Haplotype analyses consistently show stronger lipid associations than any single SNP from this block. The rs2000813 T allele tags a 5'UTR regulatory variant (rs34474737) that reduces LIPG promoter activity; individuals carrying the full TTACA haplotype carry both the rs9951026 A allele and the rs2000813 T allele, with the combined haplotype showing stronger LDL and apoB associations than either SNP alone.

The gene-physical inactivity interaction found for nearby rs6507931 (LIPG i24582) in the GOLDN study — where screen time above 2.6 h/day reduced HDL-C and HDL particle size specifically in TT carriers — suggests a general pattern of LIPG-activity interaction across the gene's haplotype structure. Users with both rs9951026 AA (high-risk LIPG haplotype) and rs2000813 CC (standard EL expression, no HDL-raising regulatory haplotype benefit) represent a combined LIPG context where aerobic activity is particularly valuable for maintaining HDL quality.

The chromosome 17q21 region is one of the most intensively studied loci in immunogenetics. A dense block of over 130 SNPs in strong linkage disequilibrium spans six genes — IKZF3, ZPBP2, GSDMB, ORMDL3, LRRC3C, and GSDMA — and has been independently associated with asthma, rheumatoid arthritis, Crohn's disease, type 1 diabetes, Graves' disease, and primary biliary cholangitis. The rs2872507 variant sits within this regulatory haploblock and influences transcription levels of ORMDL3 and GSDMB¹¹ influences transcription levels of ORMDL3 and GSDMB
rs2872507 genotype correlates strongly with ORMDL3 gene expression in airway cells; GG=highest, AA=lowest expression in a genotype-dependent manner.

IKZF3 encodes Aiolos, a zinc finger transcription factor in the Ikaros family. Aiolos is essential for B cell maturation and plasma cell differentiation²² Aiolos is essential for B cell maturation and plasma cell differentiation
Aiolos regulates B cell activation and maturation, Th17 differentiation, and NK cell maturation and plays a non-redundant role in silencing IL-2 expression in developing Th17 cells³³ silencing IL-2 expression in developing Th17 cells
Aiolos binds directly to the IL-2 promoter and triggers chromatin modifications that shut down IL-2 transcription, promoting Th17 polarization, thereby facilitating Th17 differentiation. Dysregulated Aiolos activity could shift the balance toward pathological Th17 responses that drive multiple autoimmune conditions.

The Mechanism

rs2872507 is a regulatory variant⁴⁴ regulatory variant
An intergenic/regulatory SNP that modulates the expression of neighboring genes rather than changing a protein sequence embedded in a complex regulatory landscape. The A and G alleles are associated with differential chromatin accessibility and transcription factor binding at this locus — 17q21 risk variants alter CTCF binding sites and affect IL-2 production by T cells⁵⁵ 17q21 risk variants alter CTCF binding sites and affect IL-2 production by T cells
Nature Communications 2016 study showed that 17q21 SNPs switch CTCF insulator binding and reshape the local enhancer landscape, altering long-range gene regulation across the entire haploblock.

ORMDL3 is the best-characterized effector gene at this locus. It encodes an endoplasmic reticulum transmembrane protein that regulates sphingolipid synthesis⁶⁶ sphingolipid synthesis
ORMDL3 is a key regulator of serine palmitoyltransferase, the rate-limiting enzyme in de novo sphingolipid biosynthesis and ER stress responses. Overexpression of ORMDL3 elevates ER stress markers and activates NF-κB and STAT3 signaling, promoting airway inflammation. The GG genotype drives approximately 60% higher ORMDL3 expression than AA in airway cells.

The Evidence

The landmark Moffatt et al. 2007 GWAS⁷⁷ landmark Moffatt et al. 2007 GWAS
994 childhood asthma cases vs 1,243 controls; 17q21 SNPs showed p<10⁻¹²; ORMDL3 expression correlated most strongly of all 17q21 genes established this locus as the strongest GWAS signal for childhood asthma⁸⁸ strongest GWAS signal for childhood asthma
SNPs on chromosome 17q21 were found to be strongly and reproducibly associated with childhood-onset asthma ever identified at the time. The G allele (and GG genotype) confers asthma susceptibility via elevated ORMDL3 expression.

Counterintuitively, the same locus shows the opposite effect in autoimmune diseases⁹⁹ opposite effect in autoimmune diseases
Li et al. 2012 showed rs2872507 A allele is protective for asthma but a risk allele for rheumatoid arthritis, Crohn's disease, and ulcerative colitis. A multiethnic GWAS for rheumatoid arthritis confirmed rs2872507 at genome-wide significance¹⁰¹⁰ confirmed rs2872507 at genome-wide significance
rs2872507 reached p=1.7×10⁻⁹ across 16,659 RA cases and 49,174 controls in European and East Asian populations, with the A allele as the RA risk allele. The bioinformatic analyses from that study pointed to IKZF3-ORMDL3-GSDMB as the causal gene cluster.

IKZF3 variants at this locus are also associated with Graves' disease¹¹¹¹ associated with Graves' disease
rs2872507 A allele showed OR=1.27 (p=0.004) for Graves' disease; no association found with Hashimoto's thyroiditis in 604 GD and 311 HT patients vs 814 controls, suggesting that the A allele promotes anti-thyroid autoimmunity specifically. In Chinese Han populations, different IKZF3 SNPs in the same LD block (notably rs907091) showed associations with SLE susceptibility¹²¹² associations with SLE susceptibility
rs907091 CC genotype protective against SLE (OR=0.38, p=0.001); rs2872507 itself showed no significant SLE association in this population, illustrating that the pleiotropic effects of this locus vary by both ancestry and the specific disease.

A pharmacogenomics study found that the AA genotype responds best to inhaled corticosteroids¹³¹³ AA genotype responds best to inhaled corticosteroids
AA genotype showed 13.3% FEV1 improvement vs 7.0% for AG and 4.9% for GG after ICS therapy (p=0.0176) — a finding explained by lower baseline ORMDL3 expression in AA individuals, leaving more room for corticosteroid-mediated suppression.

Practical Implications

The clinical picture for rs2872507 depends on which end of the spectrum is relevant to you. For autoimmune disease risk (RA, Crohn's, Graves' thyroiditis), the A allele — and particularly the AA genotype — confers elevated risk through IKZF3/Aiolos-mediated effects on B cell activation and Th17 regulation. For asthma, the GG genotype is the risk profile; the A allele carriers have lower ORMDL3 expression and less airway hyperreactivity. In the autoimmune-inflammation context, carriers of the A allele should be alert to early signs of inflammatory arthritis, thyroid dysfunction, and intestinal inflammation, especially when combined with other autoimmune risk variants.

Periodic monitoring of inflammatory markers (CRP, ESR) and organ-specific autoantibody panels (anti-CCP for RA, anti-TPO for thyroid disease, calprotectin for intestinal inflammation) can enable early detection of subclinical autoimmunity at the stage when intervention is most effective.

Interactions

The 17q21 locus lies in strong LD, meaning rs2872507 is in linkage with multiple other functional variants including rs8076131, rs12936231, and rs907091. The independent RA risk in this region has been confirmed across rs2872507 alongside contributions from PTPN22 (rs2476601) and HLA loci. Because IKZF3/Aiolos directly regulates Th17 cell polarization — a central pathway in RA, Crohn's disease, and psoriatic arthritis — compound risk from multiple Th17-pathway variants (e.g. IL23R, IL17A variants in other categories) may amplify the effect. The rs2476601 (PTPN22 R620W) and rs2872507 (IKZF3) combination warrants compound action consideration given independent contributions to autoimmune risk through distinct but converging pathways (T-cell tolerance vs. Th17 differentiation).

The PICALM gene¹¹ The PICALM gene
PICALM (Phosphatidylinositol binding clathrin assembly protein) orchestrates clathrin-mediated endocytosis, a cellular process critical for transporting molecules across cell membranes. Located on chromosome 11q14.2, PICALM is expressed most abundantly in brain microvessels—the endothelial cells forming the blood-brain barrier—where it plays a central role in clearing toxic amyloid-beta (Aβ) peptides from the brain. The rs3851179 variant, situated approximately 88 kb upstream of the PICALM gene, has emerged as one of the most consistently replicated genetic risk factors for late-onset Alzheimer's disease after APOE and BIN1.

The Mechanism

PICALM regulates the blood-brain barrier's ability to clear amyloid-beta from the brain into the bloodstream²² PICALM regulates the blood-brain barrier's ability to clear amyloid-beta from the brain into the bloodstream
The protein facilitates clathrin-dependent internalization of Aβ bound to LRP1 (low density lipoprotein receptor-related protein-1), a key clearance receptor, and guides the Aβ-LRP1 complex to endosomes for transcytosis—transport across the endothelial cell wall. The rs3851179 T allele, which is protective against Alzheimer's, correlates with increased PICALM expression in brain endothelium³³ The rs3851179 T allele, which is protective against Alzheimer's, correlates with increased PICALM expression in brain endothelium
In contrast, reduced PICALM expression—associated with the G allele—impairs Aβ clearance, accelerates Aβ accumulation in the brain, and correlates with cognitive impairment.

The variant is intergenic, located in a regulatory region between PICALM and the EED gene⁴⁴ The variant is intergenic, located in a regulatory region between PICALM and the EED gene
It does not change the PICALM protein sequence but appears to affect gene expression levels. PICALM is also linked functionally to ABCB1/P-glycoprotein, another Aβ clearance protein, suggesting a coordinated transcytosis system for removing brain-derived amyloid⁵⁵ PICALM is also linked functionally to ABCB1/P-glycoprotein, another Aβ clearance protein, suggesting a coordinated transcytosis system for removing brain-derived amyloid.

The Evidence

The initial discovery came from a genome-wide association study of over 5,000 Alzheimer's patients and 10,000 controls⁶⁶ The initial discovery came from a genome-wide association study of over 5,000 Alzheimer's patients and 10,000 controls
Carriers of the T allele showed a 15% reduced risk of Alzheimer's disease (OR 0.85, p=1.9×10⁻⁸). This association has been replicated across multiple ethnicities⁷⁷ This association has been replicated across multiple ethnicities
A 2016 meta-analysis of 9,435 samples confirmed the association in Chinese populations, and a 2018 systematic review of 16 case-control studies across Caucasian and Asian populations found significant associations in all genetic models examined⁸⁸ a 2018 systematic review of 16 case-control studies across Caucasian and Asian populations found significant associations in all genetic models examined.

The protective effect of the T allele remains evident even in APOE ε4 non-carriers⁹⁹ The protective effect of the T allele remains evident even in APOE ε4 non-carriers
suggesting PICALM acts through a mechanism independent of APOE. Interestingly, the T allele shows protective effects not only for Alzheimer's but also for Parkinson's disease in some populations¹⁰¹⁰ Interestingly, the T allele shows protective effects not only for Alzheimer's but also for Parkinson's disease in some populations, highlighting PICALM's broader role in neurodegeneration.

Functional studies demonstrate that the T allele is associated with increased PICALM mRNA expression in brain tissue¹¹¹¹ Functional studies demonstrate that the T allele is associated with increased PICALM mRNA expression in brain tissue
particularly in microvessels, and that this increase correlates with greater amyloid-beta clearance capacity. Mouse models with reduced Picalm expression show accelerated Aβ pathology and cognitive deficits, which can be reversed by restoring endothelial PICALM expression¹²¹² Mouse models with reduced Picalm expression show accelerated Aβ pathology and cognitive deficits, which can be reversed by restoring endothelial PICALM expression.

Practical Implications

While you cannot change your PICALM genotype, understanding your genetic risk profile can inform proactive strategies. The CC genotype confers modestly increased Alzheimer's risk, but this is just one piece of a multifactorial puzzle. Lifestyle factors—cardiovascular health, cognitive engagement, exercise, and sleep quality—significantly influence Alzheimer's risk regardless of genetics.

PICALM's role in vascular amyloid clearance underscores the importance of maintaining blood-brain barrier integrity¹³¹³ PICALM's role in vascular amyloid clearance underscores the importance of maintaining blood-brain barrier integrity
Cardiovascular risk factors (hypertension, diabetes, high cholesterol) damage the blood-brain barrier and impair its clearance function. Managing these factors may help compensate for genetic vulnerabilities in the PICALM pathway.

Interactions

The PICALM rs3851179 variant does not operate in isolation. While the protective effect of the A allele is independent of APOE ε4 status, individuals carrying both APOE ε4 and the PICALM GG genotype face compounded Alzheimer's risk through different mechanisms—APOE affects amyloid aggregation and clearance through lipoprotein pathways, while PICALM regulates transcytosis across the blood-brain barrier. Other Alzheimer's risk genes including BIN1, CLU (clusterin), and CR1 (complement receptor 1) may also interact with PICALM in the broader context of brain amyloid homeostasis. The rs3851179 variant is in high linkage disequilibrium with other PICALM-region SNPs including rs10792832, rs561655, and rs541458, all of which show genome-wide significant associations with Alzheimer's disease.

CYP2C19 is a drug-metabolizing enzyme with enormous clinical significance, particularly for the antiplatelet drug clopidogrel (Plavix). The *2 allele¹¹ rs4244285 is the most common loss-of-function variant, rendering the enzyme completely non-functional. This variant carries an FDA black-box warning²² FDA black-box warning
Clopidogrel (Plavix) prescribing label, FDA on the clopidogrel label - one of the clearest examples of pharmacogenomics directly affecting prescribing decisions.

The Mechanism

The CYP2C19*2 variant is a synonymous change (G>A at position 681 in exon 5) that creates an aberrant splice site³³ Despite being synonymous at the protein level, this variant disrupts normal mRNA splicing, producing a truncated, non-functional protein. Although the nucleotide change itself does not alter the encoded amino acid (Pro227=), it introduces a cryptic splice site that shifts the reading frame, leading to a premature stop codon. Homozygous carriers (AA) have no CYP2C19 activity and are classified as poor metabolizers.

The Clopidogrel Crisis

Clopidogrel is a prodrug⁴⁴ A prodrug is inactive until the body converts it to its active form that REQUIRES CYP2C19 to be converted to its active antiplatelet metabolite. Poor metabolizers who take clopidogrel after coronary stent placement have significantly higher rates of stent thrombosis, heart attack, and cardiovascular death. A landmark study by Mega et al.⁵⁵ landmark study by Mega et al.
Mega JL et al. Reduced-function CYP2C19 genotype and risk of cardiovascular events. JAMA, 2010 confirmed this association across multiple trials, leading to the FDA black-box warning⁶⁶ FDA black-box warning
Clopidogrel (Plavix) prescribing label, FDA.

Beyond Clopidogrel

CYP2C19 also metabolizes proton pump inhibitors (PPIs like omeprazole and pantoprazole), certain antidepressants (citalopram, escitalopram, sertraline), and antifungal agents (voriconazole). For PPIs, poor metabolizers actually benefit because the drug stays active longer, providing better acid suppression. For antidepressants, poor metabolizers may need dose reductions.

What You Should Do

If you are a poor metabolizer (AA), the clopidogrel information is potentially life-saving. If you ever need antiplatelet therapy (after a stent, stroke, or peripheral vascular disease), you MUST use an alternative like prasugrel or ticagrelor. Share this information with your cardiologist and keep it in your medical records.

The histamine H1 receptor (HRH1) sits at the front line of the allergic response. When mast cells and basophils release histamine — triggered by allergens, infections, certain foods, or stress — H1R is the molecular switch that converts that signal into the familiar cascade of sneezing, itching, swollen tissue, and bronchoconstriction. How readily and how intensely your body responds to histamine depends in part on how many H1R receptors are actually expressed on your cell surfaces.

The rs4684059 variant sits within an intron of the HRH1 gene on chromosome 3p25.3. Intronic variants in this region tag functional haplotypes that alter HRH1 transcriptional regulation¹¹ transcriptional regulation
the process by which DNA is read into RNA, controlling how much of a protein is made. The C allele is carried by roughly 36% of the global population, with frequencies reaching 43% in East Asian and European populations.

The Mechanism

The HRH1 gene contains a large 5' intron (~5.8 kb) immediately upstream of the start codon — a structural feature shared across the G-protein-coupled receptor superfamily. Variants within this region influence gene expression levels²² gene expression levels
how much HRH1 receptor protein is produced rather than changing the receptor's amino acid sequence. Lower receptor density means weaker histamine signaling per unit of histamine released; higher density means stronger, more persistent allergic responses.

A functional study of HRH1 genotypes in oral epithelial cells found that cells carrying the minor-allele genotypes of related HRH1 intronic variants expressed significantly lower HRH1 protein compared to reference-homozygote cells ³³ Ding et al. PMC9186772, 2022. This expression difference provides the biological basis for genotype-dependent variation in histamine sensitivity and antihistamine response.

The Evidence

The pharmacogenomics of HRH1 polymorphisms is an emerging research area. The best-studied HRH1 variant, rs901865 (-17C/T), tags the same gene region and has documented effects on receptor expression and antihistamine pharmacodynamics.

A case-control study in 389 Chinese Han subjects found that HRH1 -17 CC homozygotes had significantly enhanced efficacy with oral H1-antihistamines for allergic rhinitis compared to CT/TT genotype carriers, while CT and TT genotypes were overrepresented among rhinitis cases — suggesting the minor T allele both increases allergic susceptibility and reduces drug response ⁴⁴ Wang et al. PMID 30168182.

A separate study of 114 Chinese patients with chronic spontaneous urticaria found that those carrying the rs901865 G/G genotype suffered significantly more severe sedation after desloratadine treatment than G/A carriers (p=0.005), implicating HRH1 receptor levels in CNS histamine signaling as well ⁵⁵ Deng et al. PMID 31406237.

In a cohort of 202 children with asthma, the HRH1 TT genotype (minor allele homozygotes) was overrepresented among those with allergic vs nonallergic asthma, particularly in African-American children (13% vs 0%, p=0.04 in a recessive model), suggesting the minor allele haplotype tags differential allergic sensitization ⁶⁶ Anvari et al. PMID 25909280.

Note: rs4684059 itself has not been independently studied in clinical trials. The evidence above derives from functionally related HRH1 intronic variants in the same gene region that likely tag overlapping haplotypes. The evidence level is therefore emerging.

Practical Actions

For individuals carrying one or two copies of the C allele, the implication is altered HRH1 expression and potentially reduced antihistamine efficacy compared to GG homozygotes. This argues for attention to histamine trigger load (dietary and environmental) and awareness that standard antihistamine dosing may be less effective.

Quercetin, a natural flavonoid found in capers, red onions, and apples, has documented H1R antagonist activity independent of the receptor expression level and can complement antihistamine therapy. Low-histamine dietary approaches reduce the substrate load reaching the receptor regardless of receptor density.

Interactions

The HRH1 receptor pathway interacts closely with histamine-degrading enzymes. Individuals who combine low-activity AOC1/DAO (diamine oxidase) variants — which reduce histamine breakdown in the gut — with C-allele HRH1 variants face a dual burden: more histamine reaching the circulation AND potentially altered receptor sensitivity. Similarly, HNMT variants that reduce intracellular histamine methylation (the dominant CNS clearance route) interact with HRH1 receptor levels to shape neurological histamine effects including alertness and sleep onset. These interactions warrant compound actions across the histamine pathway.

The liver performs hundreds of metabolic tasks simultaneously, and one of the most consequential is converting cholesterol into bile acids — detergent-like molecules that emulsify dietary fat and carry metabolic waste out of the body. This process is tightly regulated, because too little bile acid impairs digestion and too much accumulates to toxic levels in hepatocytes. The transcription factor HNF4A (hepatocyte nuclear factor 4 alpha)¹¹ HNF4A (hepatocyte nuclear factor 4 alpha)
A nuclear receptor expressed in liver, pancreas, kidney, and intestine; controls expression of genes involved in glucose metabolism, lipid transport, bile acid synthesis, and drug metabolism sits at the center of this regulation as one of the primary transcriptional activators of the bile acid synthesis pathway.

rs6017340 is an intronic variant within the HNF4A gene on chromosome 20 that functions as a tag SNP — a marker in linkage disequilibrium with nearby functional variants that influence HNF4A expression or regulatory activity. Alone, an intronic variant does not alter protein sequence; its significance comes from what nearby variants it represents in a given haplotype block. The C allele at this position tags haplotypes that, in at least one cohort study, were associated with faster progression of a cholestatic liver disease driven by bile acid accumulation.

The Mechanism

HNF4A acts as a master transcriptional activator of CYP7A1²² CYP7A1
Cholesterol 7alpha-hydroxylase — the rate-limiting enzyme converting hepatic cholesterol to primary bile acids; accounts for ~50% of total daily cholesterol disposal in humans (cholesterol 7alpha-hydroxylase), the rate-limiting enzyme of the classic bile acid synthesis pathway. When HNF4A binds to the CYP7A1 promoter, it activates transcription and ramps up bile acid production. Experimental studies confirm that reducing HNF4A occupancy at the CYP7A1 promoter — whether through glucagon-mediated phosphorylation³³ glucagon-mediated phosphorylation
Song & Chiang 2006 — glucagon-cAMP pathway phosphorylates HNF4alpha, reducing its promoter binding and suppressing CYP7A1 transcription or through upstream transcriptional regulators — directly lowers bile acid output. Conversely, higher HNF4A activity means more CYP7A1, more bile acid synthesis, and higher hepatic bile acid flux.

Haplotypes tagged by the C allele at rs6017340 are proposed to influence this regulatory equilibrium. If C-tagging haplotypes are associated with elevated HNF4A activity in liver tissue, the result would be greater CYP7A1-driven bile acid production. In individuals with intact bile acid clearance, this excess is excreted harmlessly. But in patients with cholestatic conditions — where bile cannot be efficiently cleared — higher bile acid synthesis rates translate directly into greater hepatocyte accumulation and accelerated liver injury.

The Evidence

The sole direct association study for rs6017340 is Inamine et al. 2013⁴⁴ Inamine et al. 2013
Inamine T et al. Association of genes involved in bile acid synthesis with the progression of primary biliary cirrhosis in Japanese patients. J Gastroenterol, 2013, which analyzed 52 tag SNPs across 11 bile acid synthesis genes in 315 Japanese patients with primary biliary cholangitis (PBC). Two HNF4A tag SNPs — rs6017340 and rs6031587 — showed significant association with disease progression. The proposed mechanism is that genetic variants activating HNF4A's role in CYP7A1 transcription elevate bile acid synthesis, worsening hepatocyte bile acid accumulation in the context of impaired biliary excretion.

This is a small, single-cohort study in an ethnically specific population, and the rsid does not appear in the GWAS Catalog and carries no ClinVar annotation. The evidence is classified as emerging — the biological mechanism is well-supported by independent literature, but the specific genetic association has not been replicated in larger studies. It is possible that rs6017340 is tagging a different causal variant that shows stronger association in Japanese populations (where the C allele reaches ~82% frequency vs ~45% in Europeans).

In the broader HNF4A context, the gene is well-established as a susceptibility locus for MODY1 (maturity-onset diabetes of the young type 1)⁵⁵ MODY1 (maturity-onset diabetes of the young type 1)
An autosomal dominant form of monogenic diabetes caused by loss-of-function HNF4A mutations; presents typically before age 25, initially responsive to sulfonylureas through rare coding mutations, and population-level HNF4A haplotypes have been associated with type 2 diabetes risk, insulin secretion, and hepatic lipid metabolism in GWAS. The rs6017340 variant is specifically associated with bile acid synthesis regulation rather than glucose homeostasis, representing a distinct functional arm of HNF4A's broad hepatic regulatory role.

Practical Implications

For carriers of the C allele, the actionable implications are confined to liver health monitoring rather than active dietary intervention. The emerging evidence links this variant specifically to progression risk in cholestatic liver disease — a condition where bile flow is impaired — rather than to general metabolic risk. Most C allele carriers will never develop PBC, which affects roughly 1 in 1,000 women (with a strong female predominance) and has a complex multifactorial etiology requiring both genetic predisposition and environmental or immunological triggers.

The most clinically useful response to the C allele is awareness of cholestatic liver disease symptoms — persistent itching (pruritus), fatigue, and right upper quadrant discomfort — and appropriate use of standard liver function testing. Ursodeoxycholic acid (UDCA), which competitively replaces more toxic bile acids and reduces CYP7A1 expression via FXR activation, is the established treatment for PBC and directly addresses the bile acid overproduction mechanism implicated by this variant.

Interactions

Within HNF4A, rs6017340 acts as a haplotype tag alongside rs6031587, and both variants were identified together in the PBC progression study. Compound heterozygosity or homozygosity at the full haplotype block likely produces stronger effects than either tag SNP captures individually.

Pathway partners include CYP7A1 variants (rs3808607 and rs3824260), which directly alter CYP7A1 promoter activity and interact with HNF4A-driven transcription. Individuals carrying both HNF4A C-tagging haplotypes and CYP7A1 promoter risk alleles may face additive upregulation of bile acid synthesis through both the transcription factor and the target gene. PPARGC1A variants were also co-identified in the same bile acid synthesis study, as PPARGC1A is an HNF4A coactivator that amplifies transcriptional output.